RH
Therapeutic Areas
Molecular Partners Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MP0533 | Acute Myeloid Leukemia (AML) | Phase 1/2 |
| MP0712 | Solid Tumors (DLL3-positive, e.g., SCLC) | Preclinical |
| MP0317 | Solid Tumors | Phase 1 |
| Logic-gated Switch-DARPins | Various Cancers | Preclinical |
| Radio-DARPin Platform | Various Cancers | Preclinical |
Leadership Team at Molecular Partners
PA
Patrick Amstutz, Ph.D.
Chief Executive Officer and Member of the Management Board, Member of the Board of Directors
AZ
Alexander Zürcher
Chief Operating Officer and Member of the Management Board
PL
Philippe Legenne, M.D.
Chief Medical Officer and Member of the Management Board
MS
Martin Steegmaier, Ph.D.
Chief Scientific Officer and Member of the Management Board
MT
Michael Tobias Stumpp, Ph.D.
EVP Projects and Member of the Management Board
RG
Renate Gloggner
EVP People and Community and Member of the Management Board
MP
Michael Pitzner
General Counsel & Compliance Officer, EVP Legal and Business Development
SL
Seth Lewis
EVP Corporate Finance
DS
Daniel Steiner, Ph.D.
SVP Research & Technology
LJ
Laura Jeanbart, Ph.D.
Head of Portfolio Management and Corporate Communications